Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AssigneeVascular Biogenics Ltd.
InventorsDror Harats, Jacob George, Gideon Halperin
Life of this patent
Estimating the term…
Abstract
Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.
Claims11
A compound having a formula:
- or pharmaceutically acceptable salts thereof, wherein:
- (i) A1 and A2 are each independently selected from the group consisting of CH2 and C═O, at least one of A1 and A2 being CH2;
- (ii) R1 is selected from the group consisting of an alkyl chain having 1-27 carbon atoms and
- wherein X is an alkyl chain having 1-24 carbon atoms, Y is selected from the group consisting of:
- —OH, —H, alkyl, alkoxy halogen, acetoxy and aromatic functional groups;
- and
- Z is selected from the group consisting of:
- and —OH,
- whereas R1 is an alkyl;
- (iii) R2 is
- wherein X is an alkyl chain having 1-24 carbon atoms, Y is selected from the group consisting of:
- —OH, —H, alkyl, alkoxy halogen, acetoxy and aromatic functional groups;
- and
- Z is selected from the group consisting of:
- and —OH,
- whereas R4 is an alkyl;
- and
- (iv) R3 is selected from the group consisting of H, acyl, alkyl, phosphocholine, phosphoethanolamine, phosphoserine, phosphocardiolipin and phosphoinositol.
A pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group having a formula:
- or pharmaceutically acceptable salts thereof, wherein:
- (i) A1 and A2 are each independently selected from the group consisting of CH2 and C═O, at least one of A1 and A2 being CH2;
- (ii) R1 is selected from the group consisting of an alkyl chain having 1-27 carbon atoms and
- wherein X is an alkyl chain having 1-24 carbon atoms, Y is selected from the group consisting of:
- —OH, —H, alkyl, alkoxy halogen, acetoxy and aromatic functional groups;
- and
- Z is selected from the group consisting of:
- and —OH,
- whereas R4 is an alkyl;
- (iii) R2 is
- wherein X is an alkyl chain having 1-24 carbon atoms, Y is selected from the group consisting of:
- —OH, —H, alkyl, alkoxy halogen, acetoxy and aromatic functional groups;
- and
- Z is selected from the group consisting of:
- and —OH,
- whereas R4 is an alkyl;
- and
- (iv) R3 is selected from the group consisting of H, acyl, alkyl, phosphocholine, phosphoethanolamine, phosphoserine, phosphocardiolipin and phosphoinositol,
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.